PMID- 37350943
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230701
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 13
DP  - 2023
TI  - A comparative study of gastric adenocarcinoma HER2 IHC phenotype and mass 
      spectrometry-based quantification.
PG  - 1152895
LID - 10.3389/fonc.2023.1152895 [doi]
LID - 1152895
AB  - INTRODUCTION: Gastric cancer is a highly heterogeneous malignant tumor of the 
      digestive system. Anti-HER2 treatment can inhibit downstream signaling pathways 
      and improve clinical treatment and outcomes in patients with HER2 protein 
      overexpression. Currently, two standard methods for evaluating HER2 expression 
      status are immunohistochemistry (IHC) and fluorescence in situ hybridization 
      (FISH). However, these low-throughput assays often produce discordant or 
      equivocal results. METHODS: In this study, we presented a new HER2 protein 
      detection method based on mass spectrometry selected reaction monitoring (MS-SRM) 
      and validated the method. We conducted a retrospective study on 118 
      formalin-fixed paraffin-embedded (FFPE) tissues from patients with advanced 
      gastric adenocarcinoma in northern China, and we compared the MS-SRM results with 
      those from IHC and correlated them with FISH. RESULTS: We established and 
      validated the upper and lower detection limits (300-700 amol/mug) for abnormal 
      HER2 protein expression in advanced gastric cancer. We also found that, among 
      samples with mixed Lauren subtypes, those with a high level of HER2 expression 
      had typical intestinal type features in pathology. DISCUSSION: This study 
      demonstrated that the MS-SRM method can overcome the limitations and deficiencies 
      of IHC, directly quantify the expression of HER2 protein in tumor cells and be 
      used as a supplement to IHC. It has the potential to be used as a companion 
      diagnosis for new drugs used to treat advanced gastric cancer. Large-scale 
      clinical validation is required.
CI  - Copyright (c) 2023 Xu, Chen, Zhang, Cong, Ning, Chen, Zhang, Zhang, Song, Meng, He, 
      Liao, Lu and Zhao.
FAU - Xu, Bin
AU  - Xu B
AD  - Pathology Department, Fushun Central Hospital, Fushun, Liaoning, China.
FAU - Chen, Hui
AU  - Chen H
AD  - Stomatology Department, Fushun Central Hospital, Fushun, Liaoning, China.
FAU - Zhang, Jingjing
AU  - Zhang J
AD  - Technology Department, Tianjin Yunjian Medical Laboratory Co. Ltd., Tianjin, 
      China.
FAU - Cong, Yanghai
AU  - Cong Y
AD  - Technology Department, Tianjin Yunjian Medical Laboratory Co. Ltd., Tianjin, 
      China.
FAU - Ning, Li
AU  - Ning L
AD  - Medical Oncology, Fushun Central Hospital, Fushun, Liaoning, China.
FAU - Chen, Limin
AU  - Chen L
AD  - Technology Department, Tianjin Yunjian Medical Laboratory Co. Ltd., Tianjin, 
      China.
FAU - Zhang, Yushi
AU  - Zhang Y
AD  - Technology Department, Tianjin Yunjian Medical Laboratory Co. Ltd., Tianjin, 
      China.
FAU - Zhang, Yong
AU  - Zhang Y
AD  - Pathology Department, Liaoning Cancer Hospital & Institute, Shenyang, Liaoning, 
      China.
FAU - Song, Zhanchun
AU  - Song Z
AD  - Circulation Department, Fushun Central Hospital, Fushun, Liaoning, China.
FAU - Meng, Yuan
AU  - Meng Y
AD  - Pathology Department, Fushun Central Hospital, Fushun, Liaoning, China.
FAU - He, Lianqi
AU  - He L
AD  - Circulation Department, Fushun Central Hospital, Fushun, Liaoning, China.
FAU - Liao, Wei-Li
AU  - Liao WL
AD  - Research and Development Department, mProbe Inc., Palo Alto, CA, United States.
FAU - Lu, Ying
AU  - Lu Y
AD  - Laboratory Medicine, Fushun Central Hospital, Fushun, Liaoning, China.
FAU - Zhao, Fengyi
AU  - Zhao F
AD  - Technology Department, Tianjin Yunjian Medical Laboratory Co. Ltd., Tianjin, 
      China.
LA  - eng
PT  - Journal Article
DEP - 20230607
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC10283037
OTO - NOTNLM
OT  - HER2
OT  - IHC
OT  - MS-SRM
OT  - gastric cancer
OT  - mixed classification
OT  - types identification
COIS- JZ, YC, LC, YuZ and FZ are employees of Tianjin Yunjian Medical Laboratory Co. 
      Ltd., Tianjin, China. WLL is an employee of mProbe Inc., Palo Alto, California, 
      USA. The remaining authors declare that the research was conducted in the absence 
      of any commercial or financial relationships that could be construed as a 
      potential conflict of interest.
EDAT- 2023/06/23 13:07
MHDA- 2023/06/23 13:08
PMCR- 2023/01/01
CRDT- 2023/06/23 10:26
PHST- 2023/01/28 00:00 [received]
PHST- 2023/04/10 00:00 [accepted]
PHST- 2023/06/23 13:08 [medline]
PHST- 2023/06/23 13:07 [pubmed]
PHST- 2023/06/23 10:26 [entrez]
PHST- 2023/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2023.1152895 [doi]
PST - epublish
SO  - Front Oncol. 2023 Jun 7;13:1152895. doi: 10.3389/fonc.2023.1152895. eCollection 
      2023.